M. Los et al., ELEVATED OCULAR LEVELS OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN PATIENTS WITH VON-HIPPEL-LINDAU-DISEASE, Annals of oncology, 8(10), 1997, pp. 1015-1022
Background: Von Hippel-Lindau disease (VHL) is a rare autosomal domina
nt inherited disorder characterized by highly vascularized rumors in v
arious organs. The abundant presence of endothelial cells in VHL tumor
s strongly suggest a role of the VHL tumor suppressor gene in the regu
lation of angiogenesis. Recently, in vitro studies have shown that the
VHL tumor suppressor gene regulates the expression of vascular endoth
elial growth factor (VEGF). We investigated whether VHL patiens have i
ncreased levels of VEGF in their body fluids. Patients and methods: Th
e concentration of VEGF was measured in fluid of the anterior chamber
of the eye, serum, urine, and fluid from renal cysts of VHL patients a
nd unaffected individuals by ELISA. In addition, levels of basic fibro
blast growth factor (bFGF), interleukin-8 (IL-8) and endothelin-l (ET-
l) were measured in urine and serum of VHL patients and control subjec
ts. Results: In 80% of the VHL patients VEGF was detectable in aqueous
fluid of the anterior chamber of their eyes. A strong positive correl
ation (r = 0.90) was found between the age of VHL patients and ocular
VEGF concentrations. At comparable age, VEGF levels in ocular fluid of
VHL patients were significantly higher (P < 0.001) than in unaffected
subjects. No correlation was found between VEGF concentration and the
presence of retinal angiomas. A 10 and 16 fold increase of VEGF conce
ntration was seen in fluid from two independent VHL-related cysts as c
ompared with VEGF serum levels of the same patient. The mean concentra
tion of VEGF in serum of VHL patients (it = 15) (319 +/- 84 pg/ml) was
higher than in matched controls (238 +/- 68 pg/ml; P = NS). The mean
concentration of VEGF in urine of VHL patients (128 +/- 36 pg/ml) was
lower than in matched controls (183 +/- 25 pg/ml; P = NS). Concentrati
ons of VEGF did not correlate with the presence of VHL-related tumors.
No differences were observed between concentrations of bFGF, IL-8 and
ET-1 in serum and urine of VHL patients and matched controls. Conclus
ions: These findings support a role for the VHL tumor suppressor gene
in the in vivo regulation of VEGF.